Elena Contreras

Dr. Elena Contreras

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2021 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
ECElena Contreras
Elena Contreras
RVRaphael Vanderstichel
Raphael Vanderstichel
CHClaire Hovenga
Claire Hovenga
RLR. Michael Lappin
R. Michael Lappin
Background Chronic stress is implicated in behavioral and health issues in cats, but methods for recognition, evaluation, and measurement of stress are lacking. Cortisol concentration is typically used as an indicator of stress. Objectives To evaluate use of an enzyme immunoassay to quantitate hair and nail cortisol concentrations (HCC and NCC) in cats and evaluate associations between HCC and NCC and behavioral, physical, and environmental correlates of chronic stress in cats. Animals Forty-eight adult, owned or community cats. Methods Cross-sectional study. Nail clippings and hair were collected from cats. Medical history and cat daily lifestyle questionnaires were completed by owners or caretakers. A commercial laboratory performed cortisol extraction and quantification using a validated enzyme immunoassay kit. Correlational and regression analyses were used to evaluate associations between HCC and NCC and behavioral, environmental, and medical factors. Results Hair and nail cortisol concentrations were significantly associated (rs = 0.70; P < .001), but HCCs varied widely within and among cats. Cats with litterbox issues had significantly increased HCC (P = .02) and NCC (P = .001) as compared to cats without litterbox issues. Cats with groomed coats had lower HCCs (P = .02) as compared to cats without groomed coats, whereas cats with dander and mats had higher NCCs (P = .01) as compared to cats without dander and mats. Conclusions and Clinical Importance The quantification of NCCs might improve identification and evaluation of chronic stress in cats. The variability of HCCs in individual cats warrants caution using this measurement in chronic stress studies.

15 February 2019 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
WWWilliam Wheat
William Wheat
LCLyndah Chow
Lyndah Chow
JCJonathan Coy
Jonathan Coy
ECElena Contreras
Elena Contreras
RLR. Michael Lappin
R. Michael Lappin
SDSteven Dow
Steven Dow
Background: Nonspecific induction of local innate immune responses by mucosally administered immunotherapy is a new approach to protection from upper respiratory tract infections. Therefore, a new liposome-toll-like receptor complex (LTC) immune stimulant was developed and investigated for its ability to activate innate immune responses in cats, both in vitro and in vivo, as part of an initial evaluation of LTC for use as an immunotherapeutic agent in cats. Objectives: We hypothesized that LTC could activate innate immune responses in cats after topical application to nasal and oropharyngeal mucosal surfaces. Animals: Mucosal immune responses to topical administration of LTC were assessed in 7 healthy, purpose-bred cats, and in vitro responses were assessed using blood samples from healthy cats. Methods: Cytokine and cellular immune responses to LTC were evaluated in blood samples, nasal lavage specimens, and pharyngeal swabs from cats, using reverse transcriptase polymerase chain reaction assays, ELISA assays, and flow cytometry. Results: Liposome-TLR complexes rapidly activated leukocytes in vitro, including upregulation of costimulatory molecule expression and cytokine production. Topical administration of LTC in healthy cats triggered rapid recruitment of monocytes to the nasal and oropharyngeal mucosa. Conclusions and Clinical Importance: Liposome-TLR complexes were found to effectively activate innate immune responses in cats after mucosal administration. These findings suggest that LTC have potential for use as a new mucosally administered immunotherapy for nonspecific protection from viral and bacterial respiratory tract infections.

1 January 2018 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
ECElena Contreras
Elena Contreras
EHE. Hodgkins
E. Hodgkins
VTV. Tynes
V. Tynes
ABA. Beck
A. Beck
FOF. Olea-Popelka
F. Olea-Popelka
MLM.R. Lappin
M.R. Lappin
Stress contributes to reactivation of feline herpesvirus-1 (FHV-1). The usage of pheromones to decrease stress in FHV-1 experimentally inoculated kittens has not previously been investigated. To determine whether a feline pheromone would lessen stress, resulting in decreased recurrence of FHV-1-associated illness in kittens. Twelve 5-month-old, purpose-bred kittens. Randomized, double-blind, placebo-controlled clinical trial. Kittens previously infected with the same dose of FHV-1 were randomized into 2 separate but identical group rooms. After a 2-week equilibration period, a diffuser containing either the pheromone or placebo was placed in each of the rooms, and the kittens acclimated for an additional 2 weeks. Every 2 weeks thereafter, for the 8-week study period, housing was alternated between kennel- and group housing. Blinded observers applied a standardized clinical and behavioral scoring rubric daily. After each 2-week period, serum cortisol concentrations and quantitative PCR for FHV-1 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) ratios were evaluated. Clinical, behavioral, and laboratory test results were compared between groups within individual and combined study periods. Sneezing occurred more frequently in the placebo group during individual (P = 0.006) and combined study periods (P = 0.001). Sleep at the end of observation periods occurred more frequently in the pheromone group during individual (P = 0.006) and combined study periods (P < 0.001). The findings suggest that the pheromone decreased stress, and the decrease in stress response may have resulted in decreased sneezing associated with FHV-1.

1 March 2019 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
ECElena Contreras
Elena Contreras
FOFrancisco Olea-Popelka
Francisco Olea-Popelka
WWWilliam Wheat
William Wheat
SDSteven Dow
Steven Dow
JHJennifer Hawley
Jennifer Hawley
RLR. Michael Lappin
R. Michael Lappin
Background Feline herpesvirus‐1 (FHV‐1) infection can result in serious morbidity and mortality, especially in kittens. Immunotherapy using liposome‐toll‐like receptor (TLR) ligand complexes (LTC) has been shown to activate innate immune responses. Objectives To determine in kittens whether mucosal administration of LTC before FHV‐1 inoculation would decrease severity of clinical signs and decrease quantities of FHV‐1 DNA in materials collected on oropharyngeal swabs. Animals Nineteen, 14‐week‐old, purpose‐bred kittens. Methods Pilot clinical trial with 2 groups of kittens allocated to either an LTC or control group. The LTC were administered into both nares and the oropharynx of the 12 LTC group kittens, and all 19 kittens were inoculated with FHV‐1 24 hours later. Clinical scores were determined daily for 28 days, and oropharyngeal mucosal materials were collected every 7 days to assess FHV‐1 DNA quantities for comparison between groups. Results Conjunctivitis was more common in kittens in the control group on Days 15‐28 (P = .01) and Days 1‐28 (P = .02). Total respiratory scores were higher in the LTC group on days 15‐28 (P = .03). The LTC group had significantly decreased FHV‐1 DNA on swabs when compared to the control group on some postinoculation days, using 2 methods of calculation. Conclusions and Clinical Importance Administration of LTC to kittens was shown to decrease FHV‐1 DNA and some manifestations of illness in kittens when administrated 24 hours before inoculation, suggesting clinical benefit.

3 December 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BZBrigita Ziogaite
Brigita Ziogaite
ECElena Contreras
Elena Contreras
JHJason E Horgan
Jason E Horgan
The objectives of this study were to evaluate the risk and predictive factors of splenic malignancy and hemangiosarcoma in dogs undergoing splenectomy at a surgical specialty clinic. Medical records, hematologic results, surgical reports, and histopathologic results from 182 dogs that underwent splenectomy for the treatment of splenic masses or nodules were reviewed retrospectively. The majority of dogs (57.7%) had benign splenic diagnoses with no malignancy. Hemangiosarcoma was diagnosed in 32.4% of the dogs. A final multivariable model indicated that thrombocytopenia, anemia, and a smaller diameter of the largest splenic nodule were risk factors for hemangiosarcoma (P<0.001), and hemoperitoneum (P = 0.01) was an additional risk factor when nodule diameter was not evaluated. There were 91 dogs that had hemoperitoneum, and 60.4% of those dogs had malignant splenic lesions. Of the 33 dogs that underwent a splenectomy for incidentally identified splenic lesions, 93.9% had benign splenic lesions. Breed size was not a significant predictor of splenic malignancy risk; however, all 6 of the German shepherds included in the study had a hemangiosarcoma diagnosis. Overall prevalence of splenic malignancy including HSA may be overestimated in some canine populations.

1 September 2018 in Topics in Companion Animal Medicine
Verified
Journal Article
Closed access
ECElena Contreras
Elena Contreras
DWDeanna R. Worley
Deanna R. Worley
RPRoss H. Palmer
Ross H. Palmer
FDFelix M. Duerr
Felix M. Duerr